Compare Sana Biotechnology Inc (SANA) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Upwork Inc — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $836.71M), while Upwork Inc trades at $8.65 (market cap $1.07B). The key difference: Upwork Inc is the larger of the two by market cap, and Sana Biotechnology Inc is more actively traded (4,507,444 versus 2,574,130). Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Upwork Inc for 38 Days on average.
| SANA | UPWK | |
|---|---|---|
Market Cap | $836.71M | $1.07B |
Volume | 4,507,444 | 2,574,130 |
Sector | Health | Industrials |
52-Week High | $5.92 | $22.11 |
52-Week Low | $2.68 | $7.84 |
Typical Hold Time | 23 Days | 38 Days |
Enterprise Value | $749.96M | $833.01M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Upwork (UPWK) trades at $8.62, up 2.62% today, with a bearish technical signal despite recent earnings beat. The company maintains strong profitability with 77.21% gross margins and 12.93% net income margin, though revenue growth has stalled at $787M for 2026. Recent insider selling and securities fraud investigations create headwinds, while analyst consensus remains positive with a $9.64 price target.
The stock presents a mixed outlook with attractive valuation metrics (P/E 10.99, P/S 1.48) offset by AI-driven competitive threats and declining active clients. Near-term resistance at $9 and support at $8 will be critical, with institutional accumulation by Bank of America providing some stability amid management selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
